Anticataleptic activity of nicotine in rats: involvement of the lateral entorhinal cortex

Ionov, Ilya D.; Pushinskaya, Irina I.; Gorev, Nicholas P; Frenkel, David D.; Severtsev, Nicholas N.

doi:10.1007/s00213-021-05870-3

Cited by 5 publications

(2 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is now evident that nAChRs not only play an important role in neuronal function and the addiction to nicotine [ 151 , 152 ] but may also serve as targets for therapeutic intervention in various neuropsychiatric/neurodegenerative disorders, including PD [ 25 , 153 , 154 ], depression [ 153 , 155 , 156 ], obsessive–compulsive disorder [ 157 , 158 ], ADHD [ 159 ], Tourette syndrome [ 160 , 161 , 162 ], mild cognitive impairment or Alzheimer’s disease [ 163 , 164 , 165 , 166 ], ischemia [ 167 ], catalepsy [ 168 ], schizophrenia [ 4 , 166 , 169 ], pain [ 147 , 170 ], energy balance [ 171 , 172 ], autoimmune disorders [ 173 ], and even sleep–wake cycle dysregulation [ 174 ]. These receptors are also expressed abundantly in a variety of immune cells, including B cells, T cells, macrophages, and microglia, and are believed to contribute to the anti-inflammatory effects of nicotine [ 175 , 176 , 177 , 178 ].…”

Section: Nachrsmentioning

confidence: 99%

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Soares,

Costa,

Ferrolho

et al. 2024

Cells

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by resting tremor, bradykinesia, rigidity, and postural instability that also includes non-motor symptoms such as mood dysregulation. Dopamine (DA) is the primary neurotransmitter involved in this disease, but cholinergic imbalance has also been implicated. Current intervention in PD is focused on replenishing central DA, which provides remarkable temporary symptomatic relief but does not address neuronal loss and the progression of the disease. It has been well established that neuronal nicotinic cholinergic receptors (nAChRs) can regulate DA release and that nicotine itself may have neuroprotective effects. Recent studies identified nAChRs in nonneuronal cell types, including glial cells, where they may regulate inflammatory responses. Given the crucial role of neuroinflammation in dopaminergic degeneration and the involvement of microglia and astrocytes in this response, glial nAChRs may provide a novel therapeutic target in the prevention and/or treatment of PD. In this review, following a brief discussion of PD, we focus on the role of glial cells and, specifically, their nAChRs in PD pathology and/or treatment.

show abstract

Section: Nachrsmentioning

confidence: 99%

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Soares,

Costa,

Ferrolho

et al. 2024

Cells

View full text Add to dashboard Cite

show abstract

“…It is now evident that nAChRs not only play an important role in neuronal function and addiction to nicotine [151,152], but may also serve as targets for therapeutic intervention in various neuropsychiatric/neurodegenerative disorders including PD [25,153,154], depression [153,155,156], obsessive-compulsive disorder [157,158] , ADHD [159], Tourette syndrome [160][161][162], mild cognitive impairment or Alzheimer's disease [163][164][165][166], ischemia [167], catalepsy [168], schizophrenia [4,166,169], pain [147,170], energy balance [171,172], autoimmune disorders [173], and even in sleepwake cycle dysregulation [174]. These receptors are also expressed abundantly in a variety of immune cells including B cells, T cells, macrophages, and microglia, and are believed to contribute to the antiinflammatory effects of nicotine [175][176][177][178].…”

Section: Nachrsmentioning

confidence: 99%

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Soares,

Costa,

Ferrolho

et al. 2024

Preprint

View full text Add to dashboard Cite

Parkinson’s disease (PD) is a progressive neurodegenerative disease characterized by resting tremor, bradykinesia, rigidity, postural instability, that also includes non-motor symptoms such as mood dysregulation. Dopamine (DA) is the primary neurotransmitter involved in this disease, but cholinergic imbalance has also been implicated. Current intervention in PD is focused on replenishing central DA, which provides remarkable temporary symptomatic relief but does not address the neuronal loss and the progression of the disease. It has been well established that neuronal nicotinic cholinergic receptors (nAChRs) can regulate DA release and that nicotine itself may have neuroprotective effects. Recent studies have identified nAChRs in nonneuronal cell types including glial cells, where they may regulate inflammatory responses. Given the crucial role of neuroinflammation in dopaminergic degeneration, and the involvement of microglia and astrocytes in this response, glial nAChRs may provide a novel therapeutic target in prevention and/or treatment of PD. In this review, following a brief discussion of PD, we focus on the role of glial cells and specifically their nAChRs in PD pathology and/or treatment.

show abstract

Editorial Expression of Concern: Anticataleptic activity of nicotine in rats: involvement of the lateral entorhinal cortex

Ionov

Pushinskaya²,

Gorev³

et al. 2022

Psychopharmacology

View full text Add to dashboard Cite

Anticataleptic activity of nicotine in rats: involvement of the lateral entorhinal cortex

Cited by 5 publications

References 43 publications

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Nicotinic Acetylcholine Receptors in Glial Cells as Molecular Target for Parkinson’s Disease

Editorial Expression of Concern: Anticataleptic activity of nicotine in rats: involvement of the lateral entorhinal cortex

Contact Info

Product

Resources

About